Biological characteristics of intratumoral [F-18]‑fluoromisonidazole distribution in a rodent model of glioma

Hatano,Toshiyuki; Zhao,Songji; Zhao,Yan; Nishijima,Ken-Ichi; Kuno,Norihito; Hanzawa,Hiroko; Sakamoto,Takeshi; Tamaki,Nagara; Kuge,Yuji

doi:10.3892/ijo.2013.1781

Biological characteristics of intratumoral [F-18]‑fluoromisonidazole distribution in a rodent model of glioma

Authors:
- Toshiyuki Hatano
- Songji Zhao
- Yan Zhao
- Ken-Ichi Nishijima
- Norihito Kuno
- Hiroko Hanzawa
- Takeshi Sakamoto
- Nagara Tamaki
- Yuji Kuge
View Affiliations

Affiliations: Central Institute of Isotope Science, Hokkaido University, Sapporo, Japan, Department of Tracer Kinetics and Bioanalysis, Graduate School of Medicine, Hokkaido University, Sapporo, Japan, Central Research Laboratory, Hitachi Ltd., Kokubunji, Tokyo, Japan, Department of Nuclear Medicine, Graduate School of Medicine, Hokkaido University, Sapporo, Japan
Published online on: January 18, 2013 https://doi.org/10.3892/ijo.2013.1781
Pages: 823-830
Copyright: © Hatano et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Accurate imaging to identify hypoxic regions in tumors is key for radiotherapy planning. [F-18]‑fluoromisonidazole ([F-18]-FMISO) is widely used for tumor hypoxia imaging and has the potential to optimize radiotherapy planning. However, the biological characteristics of intratumoral [F-18]-FMISO distribution have not yet been fully investigated. In hypoxic cells, the hypoxia-inducible factor-1 (HIF-1) target proteins that induce cellular proliferation and glucose metabolism, glucose transporter-1 (Glut-1) and hexokinase-II (HK-II), are upregulated. In this study, we determined the intratumoral distribution of [F-18]-FMISO by autoradiography (ARG) and compared it with pimonidazole uptake, expression of Glut-1, tumor proliferative activity (Ki-67 index) and glucose metabolism ([C-14]2-fluoro-2-deoxy-D-glucose uptake; [C-14]-FDG) in a glioma rat model. Five C6 glioma‑bearing rats were injected with [F-18]-FMISO and [C-14]-FDG. After 90 min, the rats were injected with pimonidazole and 60 min later, the rats were sacrificed and tumor tissues were sectioned into slices. The adjacent slices were used for ARG and immunohistochemical (IHC) analyses of pimonidazole, Glut-1 and Ki-67. [F-18]-FMISO ARG images were divided into regions of high [F-18]-FMISO uptake (FMISO+) and low [F-18]-FMISO uptake (FMISO-). Pimonidazole and Glut-1 expression levels, Ki-67 index and [C-14]-FDG distribution were evaluated in the regions of interest (ROIs) placed on FMISO+ and FMISO-. [F-18]-FMISO distribution was generally consistent with pimonidazole distribution. The percentage of positively stained areas (% positive) of Glut-1 in FMISO+ was significantly higher compared to FMISO- (24±8% in FMISO+ and 9±4% in FMISO-; P<0.05). There were no significant differences in Ki-67 index and [C-14]-FDG uptake between FMISO+ and FMISO- (for Ki-67, 10±5% in FMISO+ and 12±5% in FMISO-, P = ns; for [C-14]-FDG, 1.4±0.3% ID̸g̸kg in FMISO+ and 1.3±0.3% ID̸g̸kg in FMISO-, P = ns). Intratumoral [F-18]-FMISO distribution reflected tumor hypoxia and expression of the hypoxia‑related gene product Glut-1; it did not, however, reflect tumor proliferation or glucose metabolism. Our findings help elucidate the biological characteristics of intratumoral [F-18]-FMISO distribution that are relevant to radiotherapy planning.

View Figures

View References

1	Brown JM and Giaccia AJ: The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 58:1408–1416. 1998.PubMed/NCBI
2	Gray LH, Conger AD, Ebert M, Hornsey S and Scott OC: The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol. 26:638–648. 1953. View Article : Google Scholar : PubMed/NCBI
3	Höckel M and Vaupel P: Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst. 93:266–276. 2001.PubMed/NCBI
4	Evans SM, Jenkins KW, Chen HI, Jenkins WT, Judy KD, Hwang WT, Lustig RA, Judkins AR, Grady MS, Hahn SM and Koch CJ: The relationship among hypoxia, proliferation, and outcome in patients with de novo glioblastoma: A pilot study. Transl Oncol. 3:160–169. 2010. View Article : Google Scholar : PubMed/NCBI
5	Evans SM, Hahn SM, Magarelli DP and Koch CJ: Hypoxic heterogeneity in human tumors: EF5 binding, vasculature, necrosis, and proliferation. Am J Clin Oncol. 24:467–472. 2001. View Article : Google Scholar : PubMed/NCBI
6	Troost EG, Laverman P, Philippens ME, et al: Correlation of [¹⁸F]FMISO autoradiography and pimonidazole immunohistochemistry in human head and neck carcinoma xenografts. Eur J Nucl Med Mol Imaging. 35:1803–1811. 2008.
7	Troost EG, Laverman P, Kaanders JH, Philippens M, Lok J, Oyen WJ, van der Kogel AJ, Boerman OC and Bussink J: Imaging hypoxia after oxygenation-modification: comparing [¹⁸F]FMISO autoradiography with pimonidazole immunohistochemistry in human xenograft tumors. Radiother Oncol. 80:157–164. 2006.PubMed/NCBI
8	Spence AM, Muzi M, Swanson KR, O’Sullivan F, Rockhill JK, Rajendran JG, Adamsen TC, Link JM, Swanson PE, Yagle KJ, Rostomily RC, Silbergeld DL and Krohn KA: Regional hypoxia in glioblastoma multiforme quantified with [¹⁸F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival. Clin Cancer Res. 14:2623–2630. 2008.
9	Eschmann SM, Paulsen F, Reimold M, Dittmann H, Welz S, Reischl G, Machulla HJ and Bares R: Prognostic impact of hypoxia imaging with ¹⁸F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med. 46:253–260. 2005.PubMed/NCBI
10	Rajendran JG, Schwartz DL, O’Sullivan J, Peterson LM, Ng P, Scharnhorst J, Grierson JR and Krohn KA: Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res. 12:5435–5441. 2006.
11	Overgaard J: Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol Res. 6:509–518. 1994.PubMed/NCBI
12	Overgaard J and Horsman MR: Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol. 6:10–21. 1996. View Article : Google Scholar : PubMed/NCBI
13	Moeller BJ and Dewhirst MW: HIF-1 and tumour radiosensitivity. Br J Cancer. 95:1–5. 2006. View Article : Google Scholar
14	Moeller BJ, Dreher MR, Rabbani ZN, Schroeder T, Cao Y, Li CY and Dewhirst MW: Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell. 8:99–110. 2005. View Article : Google Scholar : PubMed/NCBI
15	Dang CV and Semenza GL: Oncogenic alterations of metabolism. Trends Biochem Sci. 24:68–72. 1999. View Article : Google Scholar
16	Kamlah F, Eul BG, Li S, Lang N, Marsh LM, Seeger W, Grimminger F, Rose F and Hänze J: Intravenous injection of siRNA directed against hypoxia-inducible factors prolongs survival in a Lewis lung carcinoma cancer model. Cancer Gene Ther. 16:195–205. 2009.
17	Le QT and Courter D: Clinical biomarkers for hypoxia targeting. Cancer Metastasis Rev. 27:351–362. 2008. View Article : Google Scholar : PubMed/NCBI
18	Reske SN, Grillenberger KG, Glatting G, Port M, Hildebrandt M, Gansauge F and Beger HG: Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma. J Nucl Med. 38:1344–1348. 1997.PubMed/NCBI
19	Aloj L, Caracó C, Jagoda E, Eckelman WC and Neumann RD: Glut-1 and hexokinase expression: relationship with 2-fluoro-2-deoxy-D-glucose uptake in A431 and T47D cells in culture. Cancer Res. 59:4709–4714. 1999.
20	Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 3:721–732. 2003. View Article : Google Scholar
21	Zhao S, Kuge Y, Yi M, Zhao Y, Hatano T, Magota K, Nishijima K, Kohanawa M and Tamaki N: Dynamic 11C-methionine PET analysis has an additional value for differentiating tumors from granulomas: An experimental study using small animal PET. Eur J Nucl Med Mol Imaging. 38:1876–1886. 2011. View Article : Google Scholar : PubMed/NCBI
22	Tang G, Wang M, Tang X, Gan M and Luo L: Fully automated one-pot synthesis of [¹⁸F]fluoromisonidazole. Nucl Med Biol. 32:553–558. 2005.
23	Oh SJ, Chi DY, Mosdzianowski C, Kim JY, Gil HS, Kang SH, Ryu JS and Moon DH: Fully automated synthesis of [¹⁸F]fluoromisonidazole using a conventional [¹⁸F]FDG module. Nucl Med Biol. 32:899–905. 2005.
24	Brown RS, Leung JY, Fisher SJ, Frey KA, Ethier SP and Wahl RL: Intratumoral distribution of tritiated fluorodeoxyglucose in breast carcinoma: I. Are inflammatory cells important? J Nucl Med. 36:1854–1861. 1995.PubMed/NCBI
25	Toyama H, Ichise M, Liow JS, Modell KJ, Vines DC, Esaki T, Cook M, Seidel J, Sokoloff L, Green MV and Innis RB: Absolute quantification of regional cerebral glucose utilization in mice by ¹⁸F-FDG small animal PET scanning and 2-¹⁴C-DG autoradiography. J Nucl Med. 45:1398–1405. 2004.PubMed/NCBI
26	Hatanaka Y, Imaoka Y, Torisu K, Kamihara Y, Hashizume K, Ichimura K, Yoshino T and Tani Y: A simplified, sensitive immunohistochemical detection system employing signal amplification based on fluorescyl-tyramide/antifluorescein antibody reaction: its application to pathologic testing and research. Appl Immunohistochem Mol Morphol. 16:87–93. 2008.
27	Sorger D, Patt M, Kumar P, Wiebe LI, Barthel H, Seese A, Dannenberg C, Tannapfel A, Kluge R and Sabri O: [¹⁸F] Fluoroazomycinarabinofuranoside (¹⁸FAZA) and [¹⁸F]Fluoromisonidazole (¹⁸FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors. Nucl Med Biol. 30:317–326. 2003.
28	Buatti J, Ryken TC, Smith MC, Sneed P, Suh JH, Mehta M and Olson JJ: Radiation therapy of pathologically confirmed newly diagnosed glioblastoma in adults. J Neurooncol. 89:313–337. 2008. View Article : Google Scholar : PubMed/NCBI
29	Kaanders JH, Wijffels KI, Marres HA, Ljungkvist AS, Pop LA, van den Hoogen FJ, de Wilde PC, Bussink J, Raleigh JA and van der Kogel AJ: Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res. 62:7066–7074. 2002.PubMed/NCBI
30	Airley R, Loncaster J, Davidson S, Bromley M, Roberts S, Patterson A, Hunter R, Stratford I and West C: Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clin Cancer Res. 7:928–934. 2001.PubMed/NCBI
31	Thorwarth D, Eschmann SM, Holzner F, Paulsen F and Alber M: Combined uptake of [¹⁸F]FDG and [¹⁸F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients. Radiother Oncol. 80:151–156. 2006.
32	Wyss MT, Honer M, Schubiger PA and Ametamey SM: NanoPET imaging of [¹⁸F]fluoromisonidazole uptake in experimental mouse tumours. Eur J Nucl Med Mol Imaging. 33:311–318. 2006.
33	Zimny M, Gagel B, DiMartino E, Hamacher K, Coenen HH, Westhofen M, Eble M, Buell U and Reinartz P: FDG - a marker of tumour hypoxia? A comparison with [¹⁸F]fluoromisonidazole and pO₂-polarography in metastatic head and neck cancer. Eur J Nucl Med Mol Imaging. 33:1426–1431. 2006.
34	Gagel B, Piroth M, Pinkawa M, Reinartz P, Zimny M, Kaiser HJ, Stanzel S, Asadpour B, Demirel C, Hamacher K, Coenen HH, Scholbach T, Maneschi P, DiMartino E and Eble MJ: pO₂ polarography, contrast enhanced color duplex sonography (CDS), [¹⁸F] fluoromisonidazole and [¹⁸F] fluorodeoxyglucose positron emission tomography: validated methods for the evaluation of therapy-relevant tumor oxygenation or only bricks in the puzzle of tumor hypoxia? BMC Cancer. 7:1132007.
35	Rajendran JG, Mankoff DA, O’Sullivan F, Peterson LM, Schwartz DL, Conrad EU, Spence AM, Muzi M, Farwell DG and Krohn KA: Hypoxia and glucose metabolism in malignant tumors: evaluation by [¹⁸F]fluoromisonidazole and [¹⁸F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res. 10:2245–2252. 2004.
36	Cherk MH, Foo SS, Poon AM, Knight SR, Murone C, Papenfuss AT, Sachinidis JI, Saunder TH, O’Keefe GJ and Scott AM: Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by ¹⁸F-Fluoromisonidazole and ¹⁸F-FDG PET. J Nucl Med. 47:1921–1926. 2006.PubMed/NCBI
37	Riesterer O, Honer M, Jochum W, Oehler C, Ametamey S and Pruschy M: Ionizing radiation antagonizes tumor hypoxia induced by antiangiogenic treatment. Clin Cancer Res. 12:3518–3524. 2006. View Article : Google Scholar : PubMed/NCBI
38	Wijffels KI, Marres HA, Peters JP, Rijken PF, van der Kogel AJ and Kaanders JH: Tumour cell proliferation under hypoxic conditions in human head and neck squamous cell carcinomas. Oral Oncol. 44:335–344. 2008. View Article : Google Scholar : PubMed/NCBI
39	Rajendran JG, Wilson DC, Conrad EU, Peterson LM, Bruckner JD, Rasey JS, Chin LK, Hofstrand PD, Grierson JR, Eary JF and Krohn KA: [¹⁸F]FMISO and [¹⁸F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression. Eur J Nucl Med Mol Imaging. 30:695–704. 2003.
40	Kubota K, Tada M, Yamada S, Hori K, Saito S, Iwata R, Sato K, Fukuda H and Ido T: Comparison of the distribution of fluorine-18 fluoromisonidazole, deoxyglucose and methionine in tumour tissue. Eur J Nucl Med. 26:750–757. 1999. View Article : Google Scholar : PubMed/NCBI
41	Dewhirst MW: Intermittent hypoxia furthers the rationale for hypoxia-inducible factor-1 targeting. Cancer Res. 67:854–855. 2007. View Article : Google Scholar : PubMed/NCBI
42	Søvik A, Malinen E and Olsen DR: Strategies for biologic image-guided dose escalation: a review. Int J Radiat Oncol Biol Phys. 73:650–658. 2009.PubMed/NCBI